FibroGen Ownership | Who Owns FibroGen?
FibroGen Ownership Summary
FibroGen is owned by 32.66% institutional investors, 1.72% insiders, and 65.62% retail investors. Armistice capital is the largest institutional shareholder, holding 6.77% of FGEN shares. Vanguard Capital Opportunity Inv is the top mutual fund, with 3.08% of its assets in FibroGen shares.
FGEN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | FibroGen | 32.66% | 1.72% | 65.62% |
| Sector | Healthcare Stocks | 279.19% | 10.62% | -189.81% |
| Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Armistice capital | 6.80M | 6.77% | $3.60M |
| Vanguard group | 5.88M | 5.85% | $3.11M |
| Primecap management co/ca/ | 4.62M | 4.59% | $2.44M |
| Acadian asset management | 3.91M | 3.89% | $2.06M |
| Blackrock | 2.41M | 2.43% | $2.15M |
| Blackrock funding, inc. /de | 2.38M | 2.36% | $1.26M |
| Jacobs levy equity management | 2.10M | 2.13% | $1.88M |
| Renaissance | 1.36M | 1.35% | $719.44K |
| Aqr capital management | 1.32M | 1.33% | $1.18M |
| Marshall wace, llp | 1.27M | 1.26% | $670.72K |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Vantage consulting group | 195.71K | 0.99% | $103.63K |
| Armistice capital | 6.80M | 0.05% | $3.60M |
| Jacobs levy equity management | 2.10M | 0.01% | $1.88M |
| Franklin street advisors inc /nc | 200.00K | 0.01% | $106.00K |
| Acadian asset management | 3.91M | 0.01% | $2.06M |
| Xtx topco | 96.03K | 0.00% | $50.84K |
| Primecap management co/ca/ | 4.62M | 0.00% | $2.44M |
| Gfg capital | 12.83K | 0.00% | $6.79K |
| Aqr capital management | 1.32M | 0.00% | $1.18M |
| Cubist systematic strategies | 287.33K | 0.00% | $256.39K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Aqr capital management | 1.32M | 0.00% | 769.59K |
| Renaissance | 1.36M | 0.00% | 605.57K |
| Cubist systematic strategies | 287.33K | 0.00% | 280.16K |
| Ubs group | 196.63K | - | 171.97K |
| Nomura | 139.60K | 0.00% | 139.60K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Primecap management co/ca/ | 4.62M | 0.00% | -5.30M |
| Blackrock | 2.41M | - | -4.56M |
| 683 capital management | - | - | -2.14M |
| Jpmorgan chase | 567.00 | - | -1.67M |
| Gsa capital partners llp | - | - | -1.10M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Nomura | 139.60K | 0.00% | 139.60K | $124.56K |
| Savvy advisors | 20.59K | 0.00% | 20.59K | $10.90K |
| Parallax volatility advisers | 10.00K | - | 10.00K | $8.92K |
| Macquarie group | 4.65K | - | 4.65K | $4.15K |
Sold Out
| Holder | Change |
|---|---|
| Zurcher kantonalbank (zurich cantonalbank) | -1.00 |
| Point72 (difc) | -13.00 |
| Nelson, van denburg & campbell wealth management group | -35.00 |
| Nisa investment advisors | -120.00 |
| Larson financial group | -500.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 56 | -20.00% | 32,974,661 | -9.03% | 32 | 2.51% | 21 | -16.00% | 15 | -37.50% |
| Dec 31, 2024 | 70 | -4.11% | 36,247,264 | -21.09% | 36 | 1.73% | 25 | 25.00% | 24 | -20.00% |
| Sep 30, 2024 | 73 | -33.64% | 45,933,468 | -18.80% | 45 | 1.40% | 22 | -59.26% | 29 | -21.62% |
| Jun 30, 2024 | 110 | -5.98% | 56,568,035 | -7.77% | 57 | 1.44% | 54 | 1.89% | 37 | -13.95% |
| Mar 31, 2024 | 117 | 11.43% | 61,332,770 | -12.47% | 63 | 1.24% | 53 | 23.26% | 43 | 30.30% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Capital Opportunity Inv | 3.11M | 3.08% | -390.09K |
| Vanguard US Total Market Shares ETF | 2.92M | 2.89% | -1.00 |
| Vanguard Total Stock Mkt Idx Inv | 2.92M | 2.89% | - |
| PRIMECAP Odyssey Aggressive Growth | 2.64M | 2.63% | -1.27M |
| PRIMECAP Odyssey Growth | 1.57M | 1.56% | -826.01K |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.38M | 1.37% | - |
| Vanguard Strategic Small-Cap Equity Inv | 898.60K | 0.89% | - |
| Fidelity Extended Market Index | 565.19K | 0.56% | 76.96K |
| Vanguard US Opportunities Ins USD Acc | 403.52K | 0.40% | -6.00K |
| Fidelity Enhanced Small Cap ETF | 361.69K | 0.36% | 527.00 |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 24, 2025 | Wettig Thane | CEO | Buy | $50.66K |
| Mar 21, 2025 | Schoeneck James A | - | Buy | $17.04K |
| Mar 20, 2025 | Schoeneck James A | - | Buy | $88.00K |
| Jun 12, 2024 | Adib Deyaa | Chief Medical Officer | Buy | $25.88K |
| Mar 07, 2024 | Wettig Thane | CEO | Buy | $95.47K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | - |
| 2025 Q1 | 3 | - |
| 2024 Q4 | - | - |
| 2024 Q3 | - | - |
| 2024 Q2 | 1 | - |
FGEN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools